Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rideau: Local Tremelimumab + Systemic Durvalumab in NMIBC
NCT05120622Phase 2Withdrawn
- Sponsor
- University of British Columbia
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab, durvalumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by University of British Columbia. Planned start Sep 2021; status: withdrawn.
02
Drugs
tremelimumabdurvalumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05120622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120622.